Does Sutro Biopharma Inc (NASDAQ:STRO) Look Expensive At $3.83? Here’s How To Know.

ZM Stock

In last trading session, Sutro Biopharma Inc (NASDAQ:STRO) saw 0.62 million shares changing hands with its beta currently measuring 1.19. Company’s recent per share price level of $3.83 trading at -$0.11 or -2.79% at ring of the bell on the day assigns it a market valuation of $294.60M. That closing price of STRO’s stock is at a discount of -60.05% from its 52-week high price of $6.13 and is indicating a premium of 47.52% from its 52-week low price of $2.01. Taking a look at company’s average trading volume volume of 986.90K if we extend that period to 3-months.

Sutro Biopharma Inc (NASDAQ:STRO) trade information

Upright in the red during last session for losing -2.79%, in the last five days STRO remained trading in the green while hitting it’s week-highest on Friday, 05/03/24 when the stock touched $3.83 price level, adding 7.26% to its value on the day. Sutro Biopharma Inc’s shares saw a change of -10.72% in year-to-date performance and have moved 11.99% in past 5-day. Sutro Biopharma Inc (NASDAQ:STRO) showed a performance of -22.15% in past 30-days.

Sutro Biopharma Inc (STRO) estimates and forecasts

Statistics highlight that Sutro Biopharma Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 48.45% of value to its shares in past 6 months, showing an annual growth rate of -64.92% while that of industry is 12.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.96% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -101.39% while estimates for its earnings growth in next 5 years are of -12.88%.

STRO Dividends

Sutro Biopharma Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Sutro Biopharma Inc (NASDAQ:STRO)’s Major holders